Overview

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Efficacy of Treat-and-extend regimen (TER) using aflibercept in diabetic macular edema (DME) will be evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
Pusan National University Hospital
Collaborator:
Novartis
Treatments:
Aflibercept